Phase II study of imatinib mesylate [Imatinib] plus hydroxyurea [hydroxycarbamide] in the treatment of patients with recurrent/progressive grade II low grade glioma.

Trial Profile

Phase II study of imatinib mesylate [Imatinib] plus hydroxyurea [hydroxycarbamide] in the treatment of patients with recurrent/progressive grade II low grade glioma.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Mar 2013

At a glance

  • Drugs Hydroxycarbamide (Primary) ; Imatinib (Primary)
  • Indications Glioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Mar 2013 Actual end date changed from Oct 2011 to Jun 2012 as reported by ClinicalTrials.gov.
    • 19 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Nov 2008 Status changed from recruiting to active, no longer recruiting, reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top